Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/20 02:18:32」(JST)

wiki en

Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 造影剤に対する即時型過敏反応：臨床症状、診断、および治療 immediate hypersensitivity reactions to radiocontrast media clinical manifestations diagnosis and treatment
2. 造影剤に対する即時型過敏反応：再発反応の予防 immediate hypersensitivity reactions to radiocontrast media prevention of recurrent reactions

English Journal

Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy.

Chicaíza-Becerra LA1, García-Molina M, Gamboa Ó.
Biomédica : revista del Instituto Nacional de Salud.Biomedica.2012 Jun;32(2):182-8. doi: 10.1590/S0120-41572012000300005.
INTRODUCTION: Contrast media can cause acute renal failure by direct toxic effects on the tubular cells and kidney ischemia. Diabetics and hospitalized patients have a greater risk of developing contrast-induced nephropathy than the general population.OBJECTIVE: The cost effectiveness of iso and low
PMID 23242291

Effect of iodixanol and ioxilan on QT interval and renal function in patients with systolic heart failure.

Chow SL1, Ng TM, Litwinski RA, Kangavari S, Weiss M.
International journal of cardiology.Int J Cardiol.2012 Jan 12;154(1):17-21. doi: 10.1016/j.ijcard.2010.08.067. Epub 2010 Sep 25.
BACKGROUND: Contrast media (CM) exposure is associated with a substantial risk of arrhythmias and nephrotoxicity. These adverse effects may be exacerbated in high-risk conditions such as heart failure, although no studies have evaluated newer CM agents in this population. This study evaluated the el
PMID 20870304

Contrast-induced nephropathy morbidity and mortality following percutaneous coronary intervention.

Brown JR, Solomon RJ.
The American journal of cardiology.Am J Cardiol.2009 Dec 15;104(12):1763. doi: 10.1016/j.amjcard.2009.08.639.
PMID 19962490

Japanese Journal

Ioxilan(Imagenil)を用いた外頸動脈造影後にせん妄を来した1例

日本医学放射線学会雑誌 62(7), 370-371, 2002-06-25
NAID 120004851351

Ioxilan(Imagenil)を用いた外頸動脈造影後にせん妄を来した1例

日本醫學放射線學會雜誌 62(7), 370-371, 2002-06-25
NAID 10009492634

Effects of Nonionic Contrast Media on Platelet Aggregation. Assessment by Particle Counting with Laser-Light Scattering.:Assessment by Particle Counting with Laser-Light Scattering

Japanese Heart Journal 42(1), 115-124, 2001
NAID 130000070677

「イオキシラン」

Ioxilan
Systematic (IUPAC) name
	1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	US: B (No risk in non-human studies);
Legal status	US: ℞-only;
Routes of; administration	intravenously
Pharmacokinetic data
Bioavailability	N/A
Protein binding	negligible
Biological half-life	2 hours
Excretion	Mostly renal
Identifiers
CAS Registry Number	107793-72-6
ATC code	V08AB12
PubChem	CID: 3743
ChemSpider	3612
UNII	A4YJ7J11TG
KEGG	D02161
ChEMBL	CHEMBL1201075
Chemical data
Formula	C18H24I3N3O8
Molecular mass	791.112
	SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C ;
	InChI InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) ; Key:UUMLTINZBQPNGF-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: ioxilan
商: イマジニール

匿名

検索

案内

案内

ioxilan